BIOMAT Database Logo BIOMAT Database Logo

Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. 1996

T D Egan, and C F Minto, and D J Hermann, and J Barr, and K T Muir, and S L Shafer
Palo Alto Veterans Administration Medical Center, Palo Alto, California, USA. tegan@anest.med.utah.edu

BACKGROUND Remifentanil is an esterase-metabolized opioid with a rapid clearance. The aim of this study was to contrast the pharmacokinetics and pharmacodynamics of remifentanil and alfentanil in healthy, adult male volunteers. METHODS Ten volunteers received infusions of remifentanil and alfentanil on separate study sessions using a randomized, open-label crossover design. Arterial blood samples were analyzed to determine drug blood concentrations. The electroencephalogram was employed as the measure of drug effect. The pharmacokinetics were characterized using a moment analysis, a nonlinear mixed effects model (NONMEM) population analysis, and context-sensitive half-time computer simulations. After processing the raw electroencephalogram to obtain the spectral edge parameter, the pharmacodynamics were characterized using an effect compartment, inhibitory maximum effect model. RESULTS Pharmacokinetically, the two drugs are similar in terms of steady-state distribution volume (VD(SS)), but remifentanil's central clearance (CLc)) is substantially greater. The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CLc of 2.9 l x min(-1), a VDss of 21.81, and a terminal half-life of 35.1 min. Corresponding NONMEM parameters for alfentanil are 0.36 l x min(-1), 34.11, and 94.5 min. Pharmacodynamically, the drugs are similar in terms of the time required for equilibration between blood and the effect-site concentrations, as evidenced by a T(12)k(e0) for remifentanil of 0.75 min [corrected] and 0.96 min for alfentanil. However, remifentanil is 19 times more potent than alfentanil, with an effective concentration for 50% maximal effect of 19.9 ng x ml(-1) versus 375.9 ng x ml(-1) for alfentanil. CONCLUSIONS Compared to alfentanil, the high clearance of remifentanil, combined with its small steady-state distribution volume, results in a rapid decline in blood concentration after termination of an infusion. With the exception of remifentanil's nearly 20-times greater potency (30-times if alfentanil partitioning between whole blood and plasma is considered), the drugs are pharmacodynamically similar.

UI MeSH Term Description Entries
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010880 Piperidines A family of hexahydropyridines.
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077208 Remifentanil A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care. 3-(4-Methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic Acid Methyl Ester,GI 87084B,GI-87084B,GI87084B,Remifentanil Hydrochloride,Remifentanil Monohydrochloride,Ultiva
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T D Egan, and C F Minto, and D J Hermann, and J Barr, and K T Muir, and S L Shafer
Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs.
April 1997, The Journal of pharmacology and experimental therapeutics,
T D Egan, and C F Minto, and D J Hermann, and J Barr, and K T Muir, and S L Shafer
Pharmacokinetics and pharmacodynamics of (+/-)-sotalol in healthy male volunteers.
November 1996, British journal of clinical pharmacology,
T D Egan, and C F Minto, and D J Hermann, and J Barr, and K T Muir, and S L Shafer
Propofol alters the pharmacokinetics of alfentanil in healthy male volunteers.
June 2001, Anesthesiology,
T D Egan, and C F Minto, and D J Hermann, and J Barr, and K T Muir, and S L Shafer
The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers.
November 1993, Anesthesiology,
T D Egan, and C F Minto, and D J Hermann, and J Barr, and K T Muir, and S L Shafer
Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers.
September 1997, Anesthesiology,
T D Egan, and C F Minto, and D J Hermann, and J Barr, and K T Muir, and S L Shafer
Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers.
September 2000, Anesthesiology,
T D Egan, and C F Minto, and D J Hermann, and J Barr, and K T Muir, and S L Shafer
Behavioral and physiological effects of remifentanil and alfentanil in healthy volunteers.
March 1999, Anesthesiology,
T D Egan, and C F Minto, and D J Hermann, and J Barr, and K T Muir, and S L Shafer
Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers.
March 2015, Clinical therapeutics,
T D Egan, and C F Minto, and D J Hermann, and J Barr, and K T Muir, and S L Shafer
Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
October 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
T D Egan, and C F Minto, and D J Hermann, and J Barr, and K T Muir, and S L Shafer
Comparative pharmacokinetics and pharmacodynamics of intravenous and oral nefopam in healthy volunteers.
June 2003, Pharmacology & toxicology,
Copied contents to your clipboard!